Shanghai Securities News, China Securities Network News, April 18th: Sunnyou Medical disclosed its 2023 annual report. During the reporting period, the company achieved operating revenue of 744.8102 million yuan, an increase of 52.46% year-on-year; net profit attributable to the parent company's owners was 227.1427 million yuan, an increase of 81.03% year-on-year; net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 204.0418 million yuan, an increase of 162.31% year-on-year. At the end of the reporting period, the company's total assets were 2,592.1205 million yuan, an increase of 9.46% year-on-year; net assets attributable to shareholders of listed companies were 2,090.9009 million yuan, an increase of 8.47% year-on-year.
Sunnyou stated that the change in operating revenue is mainly due to the company’s continuous focus on new product development, enriching its rehabilitation product line, improving product quality and service standards, refining its business model, and strengthening the layout of its marketing network and the construction of its marketing system. With the ongoing support of national policies and the growing demand for rehabilitation medical services in China, the company's market competitiveness has been continuously enhanced, its market share has expanded, driving a rapid increase in the company’s operating revenue.
In 2023, the company plans to distribute a cash dividend of RMB 5.30 (including tax) for every 10 shares to all shareholders, totaling RMB 82.5947 million (including tax), demonstrating strong corporate responsibility and a shareholder-oriented approach.
In 2024, the company will adhere to a dividend payout ratio of no less than 30%, implementing a "long-term, stable, and sustainable" shareholder value return mechanism to enhance the sense of gain for the broad investor base.
Sunnyou Medical Continues to Strengthen R&D Innovation Investment, Receives Recognition from Multiple National-level R&D Platforms. In 2022, the company's technology center was recognized as a "National Enterprise Technology Center" by the National Development and Reform Commission and other departments; in 2023, the company’s "National Enterprise Technology Center" passed the reevaluation; in 2023, the company’s industrial design center was recognized as a "National Industrial Design Center" by the Ministry of Industry and Information Technology, adding another national-level R&D platform. The successive promotion of the dual centers highlights the company's R&D strength and industrial design innovation capabilities. As a national high-tech enterprise and one of the first batch of specialized, refined, distinctive, and innovative "little giant" enterprises in China, the company has always emphasized technological innovation and product upgrades, continuously increasing R&D investment to build long-term core competitive advantages. From 2021 to 2023, the company's R&D investments were 68.6058 million yuan, 92.4091 million yuan, and 106.7478 million yuan, respectively. The company continues to increase R&D expenditure and product development efforts, establishing new R&D centers in Xi'an, Hangzhou, and other places in 2024, further enhancing the overall R&D capabilities of the company. (Wang Lei)